ArriVent BioPharma, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-55.8M | $-55.8M | — | $895.0K |
| FY2024 | $-70.2M | $-70.2M | — | $3.2M |
| FY2025 | $-160.6M | $-160.6M | — | $12.5M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-55.8M | $-55.8M | — | $895.0K |
| FY2024 | $-70.2M | $-70.2M | — | $3.2M |
| FY2025 | $-160.6M | $-160.6M | — | $12.5M |